Pierre Caloz
Chief Operating Officer bij UNIQURE N.V.
Vermogen: 616 944 $ op 31-03-2024
Profiel
Pierre Caloz is currently the Chief Operating Officer at uniQure NV since 2021.
Prior to this, he worked as the SVP, GM-European Union & Asia Pacific Operations at CSL Behring NV.
Caloz completed his undergraduate degree from the University of Geneva in 1996, followed by a graduate degree from the Swiss Federal Institute of Technology in 1997.
He also holds an MBA from Ashridge Business School, which he completed in 2010.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
UNIQURE N.V.
0.25% | 01-03-2024 | 118 643 ( 0.25% ) | 616 944 $ | 31-03-2024 |
Actieve functies van Pierre Caloz
| Bedrijven | Functie | Begin |
|---|---|---|
| UNIQURE N.V. | Chief Operating Officer | 17-05-2021 |
Eerdere bekende functies van Pierre Caloz
| Bedrijven | Functie | Einde |
|---|---|---|
CSL Behring NV
 CSL Behring NV BiotechnologyHealth Technology CSL Behring NV engages in the research and development of biotherapies for the treatment of rare and severe illnesses. It offers hematology, immunology, pneumology and specific medicine. The company was founded on February 15, 1995 and is headquartered in Mechelen, Belgium. | Corporate Officer/Principal | - |
Opleiding van Pierre Caloz
| University of Geneva | Undergraduate Degree |
| Swiss Federal Institute of Technology | Graduate Degree |
| Ashridge Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| UNIQURE N.V. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
CSL Behring NV
CSL Behring NV BiotechnologyHealth Technology CSL Behring NV engages in the research and development of biotherapies for the treatment of rare and severe illnesses. It offers hematology, immunology, pneumology and specific medicine. The company was founded on February 15, 1995 and is headquartered in Mechelen, Belgium. | Health Technology |
